CN104873626A - Tablet for treating anaphylactoid purpura - Google Patents
Tablet for treating anaphylactoid purpura Download PDFInfo
- Publication number
- CN104873626A CN104873626A CN201510293025.XA CN201510293025A CN104873626A CN 104873626 A CN104873626 A CN 104873626A CN 201510293025 A CN201510293025 A CN 201510293025A CN 104873626 A CN104873626 A CN 104873626A
- Authority
- CN
- China
- Prior art keywords
- parts
- tablet
- anaphylactoid purpura
- purpura
- herba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention belongs to the field of traditional Chinese medicine and provides a tablet for treating anaphylactoid purpura. The tablet comprises, by weight, 15 parts of red bartsia, 18 parts of Sedum leucocarpum Franch., 20 parts of panax japonicus majoris, 15 parts of potentilla multifida, 12 parts of thesium chinense and 13 parts of Syzygium buxifolium Hook. et Arn.. The tablet can treat anaphylactoid purpura.
Description
Technical field
The present invention relates to technical field of Chinese medicines, be specifically related to a kind of tablet and the preparation method and application that treat anaphylactoid purpura.
Background technology
Anaphylactoid purpura is a kind of allergic angiitis of invading skin and the tiny tremulous pulse of other organs and blood capillary, often accompany stomachache, arthralgia and renal damage, but platelet does not reduce.May be relevant with streptococcal infection, viral infection, medicine, food, insect bite etc., be apt to occur in child and teenager, start to have heating, headache, arthralgia, general malaise etc.Skin lesion shows as syringe needle to Semen Glycines size petechia, ecchymosis or urticaria sample erythra, and vesicle, blood blister can occur severe patient, even ulcer.Be apt to occur in extremity and stretch side, especially two lower limb and buttocks.Skin lesion is symmetrical, occurs in batch, easily recurs.Only have skin lesion person to claim simple purpura, with suffering from abdominal pain, suffering from diarrhoea, have blood in stool, even gastrointestinal hemorrhage person is called gastrointestinal type purpura; Schoenlein purpura is called with arthroncus, pain, even hydrarthrosis person; Companion hematuria, albuminuria, renal damage person is called renal purpura.Lack effective medicine at present.
Summary of the invention
Goal of the invention: in order to solve the problem, the object of the present invention is to provide a kind of tablet and the preparation method and application that treat anaphylactoid purpura.
Technical scheme: the object of the invention is by following scheme realize:
Treat a tablet for anaphylactoid purpura, it is prepared by the raw material of following parts by weight: Herba Odontitis serotinae 15 parts, Hemerocallis citrina Baroni Herba Sedi Leucocarpi 18 parts, Rhizoma Panacis Majoris 20 parts, Potentilla multifida L. 15 parts, Herba Thesii 12 parts, Niu Jinzi 13 parts.
The application of tablet in preparation treatment allergy purpura of described treatment anaphylactoid purpura.
Herba Odontitis serotinae in the present invention, Latin is called Odontites vulgaris Moench, Scrophulariaceae Bartsia annual herb, high 20-70cm.Herb is lied prostrate by towel and the raw thin bristle of white.Stem top branch, four prismatics.Leaf to life, the alternate on top sometimes; Stockless; Blade lanceolar is to strip lanceolar, and it is raw that fringe closes inflorescence top; The florescence 7-8 month.Heat clearing and damp drying, cooling blood and relieving pain.For hot infectious disease, liver and gall stagnant heat, blood stasis is had a pain.The present invention is with all herbal medicine.
Hemerocallis citrina Baroni Herba Sedi Leucocarpi is Crassulaceae sengreen Hemerocallis citrina Baroni Herba Sedi Leucocarpi SedumleucocarpumFranch., with all herbal medicine.Autumn adopts, and dries or using fresh herb, heat clearing and inflammation relieving, and for hepatitis, otitis media is controlled in external, burn and scald.
Rhizoma Panacis Majoris derives from Araliaceae, Panax, the dry root stock of Panax pseudoginseng Wall. Subgenus Rhizoma Panacis Majoris Panax pseudoginseng Wall.var.major (Burkill) H.L.Li, tonifying the lung, and yin nourishing is active, hemostasis.For deficiency of both QI and YIN, dysphoria with smothery sensation is thirsty, cough due to consumptive disease, injury from falling down, arthralgia, hemoptysis, spits blood, traumatic hemorrhage.
Potentilla multifida L. is Rosaceae potentilla plants Potentilla multifida L. Potentilla multifida L., is used as medicine with whole herb with root.Autumn excavates, and cleans, dries, clearing away heat-damp and promoting diuresis, hemostasis, parasite killing.For hepatitis, enterobiasis, dysfunctional uterine hemorrhage, traumatic hemorrhage.
Herba Thesii is the herb of Santalaceae plant Herba Thesii ThesiumchinenseTurcz..Blazon South China, northern various places.Heat-clearing and toxic substances removing, separates administration.For enteritis, lung abscess, tonsillitis, middle administration, acute mastitis, tuberculous lymphadenitis, acute cystitis.
Cattle gold is Myrtaceae syzygium species plant Radix Syzygii Buxifolii Jambul Syzygium buxifolium Hook.et Arn., is used as medicine with root or root bark.Xia Qiu gathers, and dries.Heat-clearing and toxic substances removing, diuresis is relievingd asthma.Root, root bark: edema, asthma; Burn and scald is controlled in external.Leaf: for panaris, furuncle, dermatitis rhus, burn and scald.The present invention is used as medicine with root.
Beneficial effect: Herba Odontitis serotinae of the present invention, Hemerocallis citrina Baroni Herba Sedi Leucocarpi heat clearing and damp drying, cooling blood and relieving pain is monarch drug, Rhizoma Panacis Majoris, Potentilla multifida L. tonifying the lung, yin nourishing, active is ministerial drug, Herba Thesii, Niu Jinzi heat-clearing and toxic substances removing are adjuvant, and obtained medicine can safe and effective treatment anaphylactoid purpura.
Detailed description of the invention
Form by the following examples, foregoing of the present invention is described in further detail again, but this should be interpreted as that the scope of the above-mentioned theme of the present invention is only limitted to following example, all technology realized based on foregoing of the present invention all belong to scope of the present invention.
1, specific embodiment 1: take Herba Odontitis serotinae 15g, Hemerocallis citrina Baroni Herba Sedi Leucocarpi 18g, Rhizoma Panacis Majoris 20g, Potentilla multifida L. 15g, Herba Thesii 12g, Niu Jinzi 13g, add 10 times of water gagings, decocts 2 hours, filters; Filtering residue adds 8 times of water gagings, decocts 1 hour, filters; Merging filtrate, concentrated, dry, add starch 20g, granulate according to a conventional method, tabletting, the tablet of adult normal's 1 day consumption must be met.Be used for the treatment of anaphylactoid purpura.Oral, every bu is taken for twice sooner or later.
2, the present invention is to the clinical research of anaphylactoid purpura
2.1, physical data: inventor collects the out-patient of 50 routine anaphylactoid purpura altogether between in March ,-2014 in August, 2011, age 19-35 year, course of disease 1-4.Be divided at random: treatment group 25 example, blank group 25 example.The two groups of data such as age, state of an illness there was no significant differences, have comparability.
Diagnostic criteria: the inspection that (1) blood is often returned: the light moderate of hemocyte increase acidophil normal or increase amount of bleeding can many anemias clotting time and bleeding time platelet count all normal for clot retration time.(2) erythrocyte sedimentation rate: most of patients erythrocyte sedimentation rate speeds.(3) anti-O: can increase.(4) serum immune globulin: serum LGA can increase.(5) routine urinalysis: albumen erythrocyte or cast can be occurred in renal involvement person urine.(6) blood urea nitrogen and base sweet: renal insufficiency person increase.(7) fecal occult blood: male form during digestive tract hemorrhage.(8) capillary fragility test: about half patient is positive.(9) renal tissue pathology: can determine nephritis change nature to treatment and prognosis be determined with directive significance.(10) there is infection, food, medicine or pollen hypersensitivity, insect bite, the medical histories such as vaccination more.(11) typical characteristic skin purpura is had, in conjunction with joint, gastrointestinal or renal symptom and history of repeated attack.(12) whole blood leukocyte and eosinophilic granulocyte increase, hemorrhage serious time, erythrocyte and hemoglobin reduce.(13) erythrocyte sedimentation rate speeds, and CPR can be positive, and serum IgA increases.(14) when having renal damage, visible hematuria and albuminuria.
2.2, test method
2.2.1 the oral the present invention for the treatment of group is according to the obtained tablet of specific embodiment 1, sooner or later each once.15 days courses for the treatment of.
2.2.2 blank group oral placebo tablet, sooner or later respectively once.15 days courses for the treatment of.
2.3, criterion of therapeutical effect and therapeutic outcome
2.3.1 criterion of therapeutical effect
Recovery from illness: clinical symptoms all disappears, and test chamber inspection is normal.Take a turn for the better: clinical symptom relief, the state of an illness is controlled, lab testing improvement or normal.Invalid: clinical symptoms is without being clearly better or increasing the weight of.
2.3.2 statistical result is treated in table 1.
Table 1 liang group comparitive study
| Group | n | Recovery from illness | Take a turn for the better | Invalid | Total effective rate (%) |
| Treatment group | 25 | 13 | 10 | 2 | 92 |
| Blank group | 25 | 1 | 1 | 23 | 8 |
Visible, the medicine that the present invention obtains can safe and effective treatment anaphylactoid purpura.
Claims (2)
1. treat a tablet for anaphylactoid purpura, it is characterized in that, it is prepared by the raw material of following parts by weight: Herba Odontitis serotinae 15 parts, Hemerocallis citrina Baroni Herba Sedi Leucocarpi 18 parts, Rhizoma Panacis Majoris 20 parts, Potentilla multifida L. 15 parts, Herba Thesii 12 parts, Niu Jinzi 13 parts.
2. treat the application of tablet in treatment allergy purpura of anaphylactoid purpura as claimed in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510293025.XA CN104873626A (en) | 2015-06-01 | 2015-06-01 | Tablet for treating anaphylactoid purpura |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510293025.XA CN104873626A (en) | 2015-06-01 | 2015-06-01 | Tablet for treating anaphylactoid purpura |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104873626A true CN104873626A (en) | 2015-09-02 |
Family
ID=53941481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510293025.XA Pending CN104873626A (en) | 2015-06-01 | 2015-06-01 | Tablet for treating anaphylactoid purpura |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104873626A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080312334A1 (en) * | 2007-06-12 | 2008-12-18 | Golden Biotechnology Corporation | Cyclohexenone compounds from antrodia camphorata to treat autoimmune diseases |
| CN104258237A (en) * | 2014-10-17 | 2015-01-07 | 孙爱华 | Traditional Chinese medicine composition for treating anaphylactoid purpura as well as preparation method and application of traditional Chinese medicine composition |
-
2015
- 2015-06-01 CN CN201510293025.XA patent/CN104873626A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080312334A1 (en) * | 2007-06-12 | 2008-12-18 | Golden Biotechnology Corporation | Cyclohexenone compounds from antrodia camphorata to treat autoimmune diseases |
| CN104258237A (en) * | 2014-10-17 | 2015-01-07 | 孙爱华 | Traditional Chinese medicine composition for treating anaphylactoid purpura as well as preparation method and application of traditional Chinese medicine composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102988469A (en) | Traditional Chinese medicine composition for preventing and treating influenza virus infection as well as preparation method and application thereof | |
| CN104258237A (en) | Traditional Chinese medicine composition for treating anaphylactoid purpura as well as preparation method and application of traditional Chinese medicine composition | |
| CN103845617B (en) | One treats invisible brightic medicament | |
| CN104689100A (en) | Traditional Chinese medicine for treatment of galactostasis and mastitis complications | |
| CN104873626A (en) | Tablet for treating anaphylactoid purpura | |
| CN103610989B (en) | A kind of Chinese medicine for the treatment of acute pyogenic cholangitis | |
| CN103316252B (en) | A kind of Chinese medicine for the treatment of hepatic fibrosis | |
| CN103655771B (en) | Treat Chinese medicine preparation of skin ulcer and preparation method thereof | |
| CN110755601A (en) | Kidney bean agglutinin plant medicine composition for treating HIV/AIDS immune reconstitution defect and preparation method and application thereof | |
| CN103599423B (en) | Traditional Chinese medicine for treating pulpitis | |
| CN103623187B (en) | A kind of Chinese medicine for the treatment of angle closure glaucoma | |
| CN103610928B (en) | A kind of Chinese medicine for the treatment of anaphy lactoid purpura nephritis | |
| CN103585470B (en) | Traditional Chinese medicine for treating pneumococcal pneumonia | |
| CN103550547B (en) | Traditional Chinese medicine for treating posthepatitic syndrome | |
| CN104688917A (en) | Traditional Chinese medicine for curing anaphylactoid purpura | |
| CN105687840A (en) | Traditional Chinese medicine preparation for treating scarlet fever and preparation | |
| CN104825651A (en) | Traditional Chinese medicine composition for treating rheumatic arthralgia | |
| CN105902699A (en) | Traditional Chinese medicine external lotion for treating infantile eczema | |
| CN105125733A (en) | Traditional Chinese medicine for treating pollinosis | |
| CN103989841A (en) | Pharmaceutical composition for treatment of epidemic hemorrhagic fever | |
| CN105327343A (en) | Medicine composition for treating chronic nephrosis and preparation method thereof | |
| CN104771705A (en) | Traditional Chinese medicine preparation for treating chronic nephritis | |
| CN109833380A (en) | For preventing and treating the composition of eczema | |
| CN105168397A (en) | Medicine composition for preventing and treating nephrosis | |
| CN104225110A (en) | Traditional Chinese medicine composition for curing microcytic hypochromic anemia and preparation method and application method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| EXSB | Decision made by sipo to initiate substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150902 |